The piggyBac transposase technology is a non-viral, gene delivery system designed for use in many different research applications. With a large cargo capacity of over 200kb, piggyBac surpasses many other transposon and viral delivery vehicles, making it the optimal choice for stable cell line creation. The high efficiency and stability of piggyBac integration events have proven effective in a variety of genomes. To date, over 750 peer-reviewed papers have been published as a result of the piggyBac technology. Hera provides piggyBac products & licenses, which include research and commercial applications for drug discovery & early development.

How piggyBac works

How it works

Step 1: Clone cargo into transposon vector. Step 2: Co-transfect Transposon and Transposase into cells.
Step 3: Transposase cuts out cargo and pastes into random TTAA sites.
Step 4: Screen clones for desired insert.
Step 5 (optional): Use Excision-only piggyBac for Footprint-Free gene editing
Features
Small to enormous gene integration (200KB+)
Very efficient
High expression
Stable, seamless removal if desired

piggyBac outperforms Leap-In transposase

Approximately 4 to 11-fold greater titers compared to conventional gene integration systems for monoclonal antibodies (mAbs) or bi- specific antibodies (BSAb)1
Only 1.4 to 1.7 greater titers compared to conventional with Leap-In2

1: Rajendra et al. (2016) Generation of Stable Chinese Hamster Ovary Pools Yielding Antibody Titers of up to 7.6 g/L Using the piggyBac Transposon System. Biotechnol. Prog., Vol. 32

2: Balasubramanian et al. (2018) Generation of high expressing Chinese Hamster Ovary cell pools using the Leap-In transposon system. Biotechnol J. 2018 Oct;13(10):e1700748